Literature DB >> 24522927

CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.

Eri Miyagi1, Sandra Kao, Venkat Yedavalli, Klaus Strebel.   

Abstract

UNLABELLED: Vif is a lentiviral accessory protein that regulates viral infectivity in part by inducing proteasomal degradation of APOBEC3G (A3G). Recently, CBFβ was found to facilitate Vif-dependent degradation of A3G. However, the exact role of CBFβ remains unclear. Several studies noted reduced Vif expression in CBFβ knockdown cells while others saw no significant impact of CBFβ on Vif stability. Here, we confirmed that CBFβ increases Vif steady-state levels. CBFβ affected expression of neither viral Gag nor Vpu protein, indicating that CBFβ regulates Vif expression posttranscriptionally. Kinetic studies revealed effects of CBFβ on both metabolic stability and the rate of Vif biosynthesis. These effects were dependent on the ability of CBFβ to interact with Vif. Importantly, at comparable Vif levels, CBFβ further enhanced A3G degradation, suggesting that CBFβ facilitates A3G degradation by increasing the levels of Vif and by independently augmenting the ability of Vif to target A3G for degradation. CBFβ also increased expression of RUNX1 by enhancing RUNX1 biosynthesis. Unlike Vif, however, CBFβ had no detectable effect on RUNX1 metabolic stability. We propose that CBFβ acts as a chaperone to stabilize Vif during and after synthesis and to facilitate interaction of Vif with cellular cofactors required for the efficient degradation of A3G. IMPORTANCE: In this study, we show that CBFβ has a profound effect on the expression of the HIV-1 infectivity factor Vif and the cellular transcription factor RUNX1, two proteins that physically interact with CBFβ. Kinetic studies revealed that CBFβ increases the rate of Vif and RUNX1 biosynthesis at the level of translation. Mutants of Vif unable to physically interact with CBFβ were nonresponsive to CBFβ. Our data suggest that CBFβ exerts a chaperone-like activity (i) to minimize the production of defective ribosomal products (DRiPs) by binding to nascent protein to prevent premature termination and (ii) to stabilize mature protein conformation to ensure proper function of Vif and RUNX1. Thus, we identified a novel mechanism of protein regulation that affects both viral and cellular factors and thus has broad implications beyond the immediate HIV field.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24522927      PMCID: PMC3993832          DOI: 10.1128/JVI.03359-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.

Authors:  Andrew Mehle; Bettina Strack; Petronela Ancuta; Chengsheng Zhang; Mark McPike; Dana Gabuzda
Journal:  J Biol Chem       Date:  2003-12-13       Impact factor: 5.157

2.  APOBEC3G incorporation into human immunodeficiency virus type 1 particles.

Authors:  Véronique Zennou; David Perez-Caballero; Heinrich Göttlinger; Paul D Bieniasz
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.

Authors:  Alexandra Schäfer; Hal P Bogerd; Bryan R Cullen
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

4.  Inhibition of protein synthesis in intact HeLa cells.

Authors:  J S Tscherne; S Pestka
Journal:  Antimicrob Agents Chemother       Date:  1975-10       Impact factor: 5.191

5.  Transcription of novel open reading frames of AIDS retrovirus during infection of lymphocytes.

Authors:  A B Rabson; D F Daugherty; S Venkatesan; K E Boulukos; S I Benn; T M Folks; P Feorino; M A Martin
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

6.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

7.  Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.

Authors:  M K Karczewski; K Strebel
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Kinetics of degradation of "short-" and "long-lived" proteins in cultured mammalian cells.

Authors:  D N Wheatley; M R Giddings; M S Inglis
Journal:  Cell Biol Int Rep       Date:  1980-12

9.  Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.

Authors:  Kun Luo; Bindong Liu; Zuoxiang Xiao; Yunkai Yu; Xianghui Yu; Robert Gorelick; Xiao-Fang Yu
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

10.  Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation.

Authors:  Mikako Fujita; Hirofumi Akari; Akiko Sakurai; Akiko Yoshida; Tomoki Chiba; Keiji Tanaka; Klaus Strebel; Akio Adachi
Journal:  Microbes Infect       Date:  2004-07       Impact factor: 2.700

View more
  13 in total

1.  Real-time visualization of chromatin modification in isolated nuclei.

Authors:  Luca Sardo; Angel Lin; Svetlana Khakhina; Lucas Beckman; Luis Ricon; Weam Elbezanti; Tara Jaison; Harshad Vishwasrao; Hari Shroff; Christopher Janetopoulos; Zachary A Klase
Journal:  J Cell Sci       Date:  2017-07-25       Impact factor: 5.285

2.  Core-binding factor subunit beta is not required for non-primate lentiviral Vif-mediated APOBEC3 degradation.

Authors:  Youwei Ai; Dantong Zhu; Cuihui Wang; Chao Su; Jian Ma; Jianzhang Ma; Xiaojun Wang
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

3.  A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.

Authors:  Sizhu Duan; Shiqi Wang; Yanan Song; Nan Gao; Lina Meng; Yanxin Gai; Ying Zhang; Song Wang; Chu Wang; Bin Yu; Jiaxin Wu; Xianghui Yu
Journal:  J Biol Chem       Date:  2020-08-19       Impact factor: 5.157

Review 4.  Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.

Authors:  Farshad C Azimi; Jeffrey E Lee
Journal:  Protein Sci       Date:  2019-11-29       Impact factor: 6.725

5.  Lineage-Specific Viral Hijacking of Non-canonical E3 Ubiquitin Ligase Cofactors in the Evolution of Vif Anti-APOBEC3 Activity.

Authors:  Joshua R Kane; David J Stanley; Judd F Hultquist; Jeffrey R Johnson; Nicole Mietrach; Jennifer M Binning; Stefán R Jónsson; Sarah Barelier; Billy W Newton; Tasha L Johnson; Kathleen E Franks-Skiba; Ming Li; William L Brown; Hörður I Gunnarsson; Adalbjorg Adalbjornsdóttir; James S Fraser; Reuben S Harris; Valgerður Andrésdóttir; John D Gross; Nevan J Krogan
Journal:  Cell Rep       Date:  2015-05-14       Impact factor: 9.423

6.  Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction.

Authors:  Sizhu Duan; Xin Yu; Chu Wang; Lina Meng; Yanxin Gai; Yan Zhou; Tiejun Gu; Bin Yu; Jiaxin Wu; Xianghui Yu
Journal:  J Virol       Date:  2022-08-11       Impact factor: 6.549

7.  Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.

Authors:  Yusuke Matsui; Keisuke Shindo; Kayoko Nagata; Noriyoshi Yoshinaga; Kotaro Shirakawa; Masayuki Kobayashi; Akifumi Takaori-Kondo
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

8.  Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta.

Authors:  Eri Miyagi; Sarah Welbourn; Sayaka Sukegawa; Helena Fabryova; Sandra Kao; Klaus Strebel
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

Review 9.  Making Sense of Multifunctional Proteins: Human Immunodeficiency Virus Type 1 Accessory and Regulatory Proteins and Connections to Transcription.

Authors:  Tyler B Faust; Jennifer M Binning; John D Gross; Alan D Frankel
Journal:  Annu Rev Virol       Date:  2017-09-29       Impact factor: 10.431

10.  ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction.

Authors:  Kei Miyakawa; Satoko Matsunaga; Kazuhiko Kanou; Atsushi Matsuzawa; Ryo Morishita; Ayumi Kudoh; Keisuke Shindo; Masaru Yokoyama; Hironori Sato; Hirokazu Kimura; Tomohiko Tamura; Naoki Yamamoto; Hidenori Ichijo; Akifumi Takaori-Kondo; Akihide Ryo
Journal:  Nat Commun       Date:  2015-04-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.